Please try another search
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Michael J. Newmann | - | - | Director |
Brian O’Callaghan | - | - | Director |
Hoonmo Lee | - | - | Director |
Roger James Pomerantz | 64 | 2018 | Independent Chairman |
Roger James Pomerantz | 66 | 2021 | Independent Chairman of the Board |
William Bradley Hayes | 57 | 2021 | Independent Director |
Jeffrey A. Meckler | 56 | 2021 | CEO & Director |
Mark J. Gilbert | 62 | 2021 | Independent Director |
Robert E. Martell | 60 | 2023 | Independent Director |
Anthony J. Maddaluna | 70 | 2021 | Independent Director |
Michael J. Newman | 67 | 2021 | Founder, Chief Scientific Officer & Director |
Hila Karah | 54 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review